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Introduction 
Inherited deficiency of dihydropteridine reduc-
tase (DHPR, EC 1.66.99.7) impairs the re-
generation of tetrahydrobiopterin (B H 4), the es-
sential cofactor of phenylalanine (Phe) , tyrosine 
(Tyr), and trypthophan (Trp) hydroxylases, which 
is oxidized to qBH2 during a coupled reaction 
with these enzymes ( 1). Hyperphenylalaninemia 
and scarce production of monoamine neu-
rotransmitters derived from Tyr and Trp-do-
pamine, norepinephrine, and serotonin-are the 
main metabolic derangements caused by DHPR 
deficiency. Untreated patients early develp a sev-
ere an progressive neurological picture , which is 
shared by other inborn errors of BH4 metabolism 
(1 ). The control of hyperphenylalaninemia and 
biogenic amine deficiency is necessary to improve 
their prognosis, together with folinic acid sup-
plementation to avoid folate depiction (2 ) . 
DHPR deficiency, however, is a heterogeneous 
disease both at clinical and molecular level. The 
dietary tolerance to Phe is highe r than in classical 
phenyketonuria, but shows interindividual dif-
ferences, as well as age-dependent increase ( 1 ). 
The control of hype rphenylalaninemia can be 
achieved either by a Phe-restricted diet or by ad-
ministration of synthetic cofactor. As in these pa-
tients some recycling of BH4 do occur (3), a daily 
dosage of 8-20 mg/ kg is sufficient to attain nor-
§ Author to whom correspondence should be addressed. 
mal serum Phe levels. 
Despite substantial amounts of peripherally ad-
ministered BH4 can be found in cerebrospinal 
fluid (CSr), only some patients respond at the 
central level to BH4 monotherapy (3,4). Most pa-
tients need neurotransmitter substitutive therapy, 
which can be realized by administering the hy-
droxylated precursors, I-Dopa and 5 -0H-Trp, in 
conjunction with an inhibitor of peripheral amino 
acid decarboxylases. Also the daily doses and the 
number of administrations of neurotransmitter 
precursors have to be individually adjusted . Ran-
dom fluctuations in response to this therapy are 
observed, especially when larger doses of 1- Dopa 
arc required, which can be obviated by the ad-
dition of a monoamine oxidase inhibitor (S ). 
As a consequence, the best choice of treatment 
must be thoroughly searched for in every patient 
affected by DHPR deficiency, as in the case here 
reported . 
Case Report and Methods 
Patient r.M., kmale, was born at term after an 
uncomplicated preg nancy as the first child of un -
related parents. Routine Guthrie testing on day 4 
showed slightly elevated blood Phe concentration 
(4 mg%) which increased up to 37 mg% on a f<:>r -
mula diet within the first month . Since then the 
infant was put on a Phe -restricted diet , bur at the 
age of 4 monthes she developed hvpert()nic crises, 
lethargia, and oculogiric crises. DHPR deficiency 
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Table 1 . Clinical and biochemical monitiring in a patient affected by dihydropteridine reductase deficiency during dif-
ferent treatments. Phe=phenylalanine; Tyr=tyrosine; Trp=tryptophan; CSF=cerebrospinal fluid; 5-HlAA=5-hy-
droxyndole acetic acid; HV A=homovanillic acid; BH4 =tetrahydrobiopterin; nd=not done. 
Serum (umol/l) CSF (nmol/l) 
Treatment Age Clinical symptoms 
Phe Tyr 5-HIAA 5-OH-Trp HVA I-Dopa 
Lethargia 
Diet only 5 mo Hypertonic crises 378 91 16 nd 128 nd Oculogiric crises 
Marked truncal hypotonia 
Diet Lethargia 
BH4(6 mg/kg/day) 
5-0H-Trp (2.5 mg/kg/day) 7mo Oculogiric crises 180 85 72 nd 474 nd 
I-Dopa (3.3 mg/kg/day) Truncal hypotonia 
Diet Oculogiric crises 5-0H-Trp (5 mg/kg/day) 8 mo 170 37 156 219 237 17 
I-Dopa (5 mg/kg/day) Reduced truncal hypotonia 
BH4monotherapy 
Lethargia 
9mo Oculogiric crises 52 43 28 173 4 (20 mg/kg/day) Marked truncal hypotonia 
Diet 
I-Deprenyl (0.25 mg/kg/day) 
5-0H-Trp (5 mg/kg/day) 
I-Dopa (5 mg/kg/day) 
9 mo No symptoms 
was ascertained at 5 months by enzyme aCtiVIty 
measurement on blood spot, urinary pterin and 
CSF analysis, and combined Phe-BH4 loading test 
( 6). 
Four different therapeutic strategies were then 
sequentially applied (BH4 and neurotransmitter 
therapy at low doses; diet plus neurotransmitter 
therapy; BH4 monotherapy; diet plus neu-
rotransmitter therapy plus monoamine oxidase m-
hibitor), and monitored either clinically or 
biochemically (Table 1). 
Serum and CSF samples were taken half way 
between two successive drug administrations. Ser-
um Phe and Tyr were measured chro-
matographically with a Kromakon 500 automatic 
analyzer. CSF concentrations of homovanillic acid 
(HVA) , 5-hydroxyndole acetic acid (5-HIAA), 
and I-DOPA were measured by HPLC with an 
ESA Coulochem 5100A eletrochemical detector. 
Results and Discussion 
Monitoring of treatment in BH4 deficiency can 
be implemented either clinically, by evaluating the 
minimal dose effective in relieving symptoms of 
biogenic amine deficiency, or biochemically, by 
measuring the CSF concentration of neurotrans-
mitter metabolites, besides the level of blood Phe 
and Tyr (2,7). Pitfalls in clinical monitoring are 
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due to the fact that dopamine and serotonin can 
produce agonist and antagonist effects, which can 
also mimic the symptoms of deficiency (2,8). On 
the other hand, a good clinical result can be 
achieved in these patients at CSF levels of HV A 
and of 5-HIAA below those of age-matched con-
trols (9). 
Data shown in Table 1 suggest that the CSF 
concentration of I-DOPA and of 5-0H-Trp are 
more tightly related to the clinical picture. BH4 
was shown to be peripherally effective in the con-
trol of hyperphenylalaninemia in this patient; at 
the central level, however, the effect was very 
poor, even at high cofactor doses, on the basis of 
both clinical and biochemical evaluation. 
As previously reported in cases of 6-pyruvoyl 
tetrahydropterin synthase and of DHPR de-
ficiency (5,10,11) the optimal results were ob-
tained by the addition to the classical treatment 
of I-Deprenyl, a selective monoamine oxidase B in-
hibitor. It should be noted, finally, that on such a 
therapy the significance of CSF HV A and 5-
HlAA concentration is lessened because of the 
limiting effect of I-Deprenyl on dopamine and 
serotonin degradation. 
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